Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy.

Autor: Jain, Arpit, Koyyala, Venkata Pradeep Babu, Narayan, Satya, Soni, Satyajeet, Redhu, Pallavi, Jaju, Akanksha
Předmět:
Zdroj: Indian Journal of Medical & Paediatric Oncology; Apr2022, Vol. 43 Issue 2, p185-188, 4p
Abstrakt: Immune checkpoint inhibitor (ICI) restores an efficient antitumor T cell response against tumor cells fostering durable responses that can persist even after the treatment. However, these treatment effects can manifest as an unusual pattern of disease progression, pseudo-progression, or hyper-progression. Differentiating hyper progressive disease (HPD) from pseudo-progression has significant clinical implications and further decision-making for the patient on ICI. HPD is a dramatic acceleration of the rate of tumor progression with the advent of immunotherapeutic agents causing detrimental effects on the disease outcome. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Nepřihlášeným uživatelům se plný text nezobrazuje